The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for ...
Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...
Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...
Ultragenyx Pharmaceutical RARE reported new findings from an ongoing, pivotal study of its investigational candidate, UX111 (ABO-102) AAV gene therapy, for Sanfilippo syndrome type A (MPS IIIA).
An Orange couple who lost their son to a rare genetic condition are determined to continue raising awareness to improve the lives of diagnosed children and their families.
Notably, older children or those with more advanced disease retained ... received several designations from the FDA that could expedite its review process. Sanfilippo syndrome type A is a rare, fatal ...
Dr. Eric Crombez, Chief Medical Officer at Ultragenyx, stated, "The data support UX111's potential to provide meaningful benefits to children with Sanfilippo Syndrome, especially for those in ...
Notably, older children or those with more advanced ... from the FDA that could expedite its review process. Sanfilippo syndrome type A is a rare, fatal condition with no approved treatment ...
Officers, deputies play basketball for a good cause “She was diagnosed with Sanfilippo Syndrome, which is also called childhood Alzheimer’s. Its neurodegenerative life expectancy is into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results